EVO News and Press, Evotec SE From 04/07/23

HAMBURG, GERMANY / ACCESSWIRE / April 7, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN:DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that on 06 April, 2023 a cyber attack occurred on Evotec‘s IT systems. As a result, the systems were shut down proactively and dis...

2023-04-05 21:43:43 ET Summary A reader asked me to take a look at German company Evotec, which also has a dual listing on NASDAQ under symbol EVO. His question was whether I view the company as a value trap, or as a significantly undervalued stock that I would be open to investin...

2023-03-28 13:18:08 ET Evotec SE (EVOTF) Q4 2022 Earnings Conference Call March 27, 2023 8:30 A.M. ET Company Participants Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Craig Johnstone - Chief Operating Officer Matthias Ev...

2023-03-28 06:24:03 ET Bristol Myers Squibb ( NYSE: BMY ) and Evotec ( NASDAQ: EVO ) have expanded their partnership for another eight years to discover and develop neurodegenerative diseases. Germany-based Evotec will get $50M upfront, undisclosed license and...

8-YEAR EXTENSION AND EXPANSION OF ONGOING COLLABORATION TO DEVELOP A BROADENED PROGRAMME PIPELINE IN NEURODEGENERATIVE DISEASES PARTNERSHIP LEVERAGES EVOTEC'S PRECISION MEDICINE PLATFORMS FINANICAL TERMS INCLUDE $ 50 M UPFRONT PAYMENT, PERFORMANCE MILESTONES AND TIERED ROYALTIES ON PROD...

22% INCREASE IN GROUP REVENUES; EBITDA EXCLUDING M&A AT € 104.1 M POSITIVE MOMENTUM AND OUTLOOK FOR 2023 DATA-DRIVEN PLATFORMS RESULTING IN LARGEST ALLIANCE IN TARGETED PROTEIN DEGRADATION IN THE INDUSTRY HAMBURG, GERMANY / ACCESSWIRE / March 28, 2023 / Evotec SE (Frank...

2023-03-24 05:15:54 ET Evotec ( NASDAQ: EVO ) ( OTCPK:EVOTF ) said it received a $6.6M grant from The Bill & Melinda Gates Foundation to discover and develop drugs for tuberculosis (TB). It is a second grant from the foundation to Evotec for TB drug discovery, and ...

GRANT FROM THE BILL & MELINDA GATES FOUNDATION SUPPORTS EVOTEC'S EFFORTS TO DISCOVER AND DEVELOP DRUG CANDIDATES FOR A UNIVERSAL, SHORTER, SAFER AND SIMPLER TUBERCULOSIS DRUG REGIMEN AS ONE OF ITS PROGRAMMES CONTRIBUTING TO THE UN SUSTAINABLE DEVELOPMENT GOAL 3 "WORLD TUBERCULOSIS DAY", ...

HAMBURG, GERMANY / ACCESSWIRE / March 21, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN: DE0005664809)(NASDAQ:EVO) will announce its preliminary financial results for 2022 on Tuesday, 28 March 2023. The Company is going to hold a conference call to discuss the results as ...

KEY SCIENTIFIC ACHIEVEMENTS DRIVE THE EXPANSION OF THE PIPELINE OF MOLECULAR GLUE DEGRADERS PERFORMANCE-BASED AND PROGRAMME-BASED PAYMENTS OF IN TOTAL US$ 75 M TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / March 16, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE00056...